Evidence map›Paper›PMID 28507604›Full record

ArticleTherapeutic advances in neurological disorders2017

Health-related quality of life outcomes from botulinum toxin treatment in hemifacial spasm.

Daniel Weiss, Justine Sturm, Leonhard Hieber, Axel Börtlein, Ingo Mayr, Matthias Appy, Benedicta Kühnler, Joachim Buchthal, Christian Dippon, Guy Arnold and 1 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in neurological disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Article
  7. Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Daniel WeissHertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Tübingen, Germany.
Justine SturmHertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Tübingen, Germany.
Leonhard HieberHertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Tübingen, Germany.
Axel BörtleinNeurologische Klinik, Klinikum Stuttgart, Stuttgart, Germany.
Ingo MayrKlinik für Neurologie Sindelfingen, Krankenhaus Sindelfingen-Böblingen, Sindelfingen, Germany.
Matthias AppyBerufsausübungsge-meinschaft Dres. Matthias Appy, Wolfgang Molt, Prof. Arthur Melms und Kollegen, Stuttgart, Germany.
Benedicta KühnlerBerufsausübungsge-meinschaft Dres. Matthias Appy, Wolfgang Molt, Prof. Arthur Melms und Kollegen, Stuttgart, Germany.
Joachim BuchthalNeurologische Gemeinschaftspraxis am Seelberg, Stuttgart, Germany.
Christian DipponNeurologische Gemeinschaftspraxis am Seelberg, Stuttgart, Germany.
Guy ArnoldKlinik für Neurologie Sindelfingen, Krankenhaus Sindelfingen-Böblingen, Sindelfingen, Germany.
Tobias WächterHertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Tübingen, Germany.
Hertie Institute for Clinical Brain Research · DEKlinikum Sindelfingen-Böblingen · DEUniversity of Tübingen · DEKlinikum Stuttgart · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough botulinum neurotoxin (BoNT) injections may alleviate involuntary muscle contractions in hemifacial spasm substantially, it is less clear whether the motor effect would translate into improvements of health-related quality of life (HR-QoL).

methodsIn this open-label clinical observational study, we characterized outcomes on HR-QoL in terms of the EuroQol (EQ-5D-5L) from BoNT in a prospective cohort of patients with hemifacial spasm (

resultsPatients showed improved HR-QoL on the EQ-VAS (visual analogue scale) at timepoint2 compared with timepoint1. Moreover, we identified, that impairments in HR-QoL at timepoint1 correlated with life satisfaction and depressive symptoms, respectively. However, these associated variables did not predict the therapeutic effect. Instead, EQ-VAS at timepoint1 accounted for 34.5% of the variance of EQ-VAS improvement expressed as the difference between timepoint2 and timepoint1.

conclusionOur study supports HR-QoL improvements in hemifacial spasm and the value of generic HR-QoL measures to estimate therapeutic outcome. However, the findings should be considered descriptive, and future high quality trials are needed for confirmatory purposes in order to refine treatment referral in hemifacial spasm with respect to QoL.

Indexed as

botulinum toxinhemifacial spasmquality of life

Identifiers

PMID28507604
PMCPMC5415226
OpenAlexW2583172580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.